[go: up one dir, main page]

DE60331559D1 - Pyrrolidonderivate als mao-b hemmer - Google Patents

Pyrrolidonderivate als mao-b hemmer

Info

Publication number
DE60331559D1
DE60331559D1 DE60331559T DE60331559T DE60331559D1 DE 60331559 D1 DE60331559 D1 DE 60331559D1 DE 60331559 T DE60331559 T DE 60331559T DE 60331559 T DE60331559 T DE 60331559T DE 60331559 D1 DE60331559 D1 DE 60331559D1
Authority
DE
Germany
Prior art keywords
hemmer
mao
pyrrolidone derivatives
pyrrolidone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331559T
Other languages
English (en)
Inventor
Hans Iding
Synese Jolidon
Daniela Krummenacher
Sarmiento Rosa Maria Rodriguez
Andrew William Thomas
Beat Wirz
Wolfgang Wostl
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60331559D1 publication Critical patent/DE60331559D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60331559T 2002-09-20 2003-09-18 Pyrrolidonderivate als mao-b hemmer Expired - Lifetime DE60331559D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010384 WO2004026827A1 (en) 2002-09-20 2003-09-18 Pyrrolidone derivatives as maob inhibitors

Publications (1)

Publication Number Publication Date
DE60331559D1 true DE60331559D1 (de) 2010-04-15

Family

ID=32010924

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60333202T Expired - Lifetime DE60333202D1 (de) 2002-09-20 2003-09-18 Pyrrolidonderivate als mao-b hemmer
DE60331559T Expired - Lifetime DE60331559D1 (de) 2002-09-20 2003-09-18 Pyrrolidonderivate als mao-b hemmer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60333202T Expired - Lifetime DE60333202D1 (de) 2002-09-20 2003-09-18 Pyrrolidonderivate als mao-b hemmer

Country Status (31)

Country Link
US (4) US7037935B2 (de)
EP (3) EP1542971A1 (de)
JP (3) JP4335141B2 (de)
KR (3) KR100676014B1 (de)
CN (3) CN100383118C (de)
AR (3) AR041299A1 (de)
AT (2) ATE459601T1 (de)
AU (3) AU2003267381B2 (de)
BR (4) BRPI0314631B1 (de)
CA (3) CA2496756C (de)
CY (1) CY1110745T1 (de)
DE (2) DE60333202D1 (de)
DK (1) DK1542970T3 (de)
ES (2) ES2344557T3 (de)
GT (3) GT200300206A (de)
HR (3) HRP20050262A2 (de)
JO (2) JO2604B1 (de)
MX (3) MXPA05002880A (de)
MY (3) MY134480A (de)
NO (3) NO330012B1 (de)
NZ (3) NZ538049A (de)
PA (3) PA8583001A1 (de)
PE (3) PE20050077A1 (de)
PL (3) PL376019A1 (de)
PT (1) PT1542970E (de)
RU (3) RU2323209C2 (de)
SI (1) SI1542970T1 (de)
TW (3) TWI286132B (de)
UY (3) UY27990A1 (de)
WO (3) WO2004026827A1 (de)
ZA (3) ZA200501137B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 b 억제제로서 벤질옥시 유도체
MX2007001169A (es) 2004-08-02 2007-03-12 Hoffmann La Roche Derivados de benciloxi como inhibidores de la oxidasa de monoamina b.
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2314877T3 (es) * 2005-03-15 2009-03-16 F. Hoffmann-La Roche Ag Metodo para preparar derivados de eter-4-pirrolidino-fenilbencilico enantiomericamente puros.
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
WO2007042250A1 (en) * 2005-10-10 2007-04-19 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
BR112015022202A2 (pt) 2013-03-14 2017-07-18 Dart Neuroscience Cayman Ltd compostos substituídos de naftiridina e quinolina como inibidores da mao
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
RU2016118748A (ru) 2013-10-29 2017-12-05 Ф. Хоффманн-Ля Рош Аг Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение
EP3237379B1 (de) 2014-12-23 2022-04-06 Convergence Pharmaceuticals Limited Verfahren zur herstellung von alpha-carboxamid-pyrrolidinderivaten
EP3273946A1 (de) * 2015-03-27 2018-01-31 F. Hoffmann-La Roche AG Pharmazeutische formulierung mit sembragilin
WO2019065794A1 (ja) 2017-09-27 2019-04-04 国立大学法人鹿児島大学 Pac1受容体拮抗薬を用いた鎮痛薬
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
CN110240557B (zh) * 2018-03-08 2023-05-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物及其用途
US20220184081A1 (en) 2019-02-27 2022-06-16 Kagoshima University Antipruritic agent using pac1 receptor antagonist
JP7049637B1 (ja) 2020-05-08 2022-04-07 国立大学法人 鹿児島大学 Pac1受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) * 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
JP2657324B2 (ja) 1989-04-19 1997-09-24 大塚製薬株式会社 ヘテロ環を有するフェニルカルボン酸誘導体
HU221138B1 (en) * 1994-08-30 2002-08-28 Sankyo Co Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (de) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Lactamverbindungen als metalloprotease, tnf-alpha und aggrecanase inhibitoren
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001058388A1 (en) * 2000-02-10 2001-08-16 Potencia Medical Ag Urinary incontinence treatment with wireless energy supply
US7442165B2 (en) * 2000-02-14 2008-10-28 Obtech Medical Ag Penile prosthesis
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
JO2604B1 (en) 2011-11-01
US20060122235A1 (en) 2006-06-08
JO2605B1 (en) 2011-11-01
CA2496756C (en) 2012-01-10
BR0314314A (pt) 2005-07-26
EP1542969A1 (de) 2005-06-22
PL376019A1 (en) 2005-12-12
PT1542970E (pt) 2010-07-19
PE20050077A1 (es) 2005-03-01
HRP20050263A2 (en) 2006-12-31
TWI337604B (en) 2011-02-21
AU2003273901A1 (en) 2004-04-08
MXPA05002878A (es) 2005-05-27
UY27990A1 (es) 2004-03-31
US7037935B2 (en) 2006-05-02
CA2498335A1 (en) 2004-04-01
ATE472530T1 (de) 2010-07-15
CA2498785A1 (en) 2004-04-01
NO329754B1 (no) 2010-12-13
RU2005111974A (ru) 2006-01-20
EP1542969B1 (de) 2010-03-03
EP1542970A1 (de) 2005-06-22
KR100676014B1 (ko) 2007-01-30
GT200300205A (es) 2004-04-29
BR0314299A (pt) 2005-12-13
KR100676015B1 (ko) 2007-01-30
AR041299A1 (es) 2005-05-11
NO330012B1 (no) 2011-02-07
US20040097578A1 (en) 2004-05-20
CA2496756A1 (en) 2004-04-01
PA8583601A1 (es) 2004-09-16
EP1542971A1 (de) 2005-06-22
NZ538046A (en) 2007-08-31
TW200413350A (en) 2004-08-01
CN100503562C (zh) 2009-06-24
KR20050057450A (ko) 2005-06-16
ZA200501137B (en) 2006-12-27
MY133332A (en) 2007-11-30
HK1084383A1 (en) 2006-07-28
RU2005111968A (ru) 2006-11-10
MXPA05002880A (es) 2005-05-27
AU2003270213B2 (en) 2009-02-12
NO20050652L (no) 2005-03-08
NO20050701L (no) 2005-03-02
UY27991A1 (es) 2004-03-31
US7235581B2 (en) 2007-06-26
RU2323209C2 (ru) 2008-04-27
WO2004026825A1 (en) 2004-04-01
HK1083498A1 (zh) 2006-07-07
JP4335141B2 (ja) 2009-09-30
US7151111B2 (en) 2006-12-19
ES2344557T3 (es) 2010-08-31
PA8583501A1 (es) 2004-04-23
PL376021A1 (en) 2005-12-12
RU2005111969A (ru) 2006-01-20
ATE459601T1 (de) 2010-03-15
HK1083499A1 (zh) 2006-07-07
SI1542970T1 (sl) 2010-08-31
DK1542970T3 (da) 2010-08-02
MY134480A (en) 2007-12-31
HRP20050262A2 (en) 2006-06-30
CN100400509C (zh) 2008-07-09
JP2006503834A (ja) 2006-02-02
JP2006510596A (ja) 2006-03-30
WO2004026827A1 (en) 2004-04-01
BR0314631A (pt) 2005-08-02
UY27993A1 (es) 2004-03-31
GT200300206A (es) 2004-04-29
PE20050079A1 (es) 2005-03-01
AU2003267381B2 (en) 2009-08-27
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
KR20050057456A (ko) 2005-06-16
TW200410935A (en) 2004-07-01
AU2003270213B8 (en) 2009-03-05
JP4335142B2 (ja) 2009-09-30
PA8583001A1 (es) 2004-04-23
TWI331994B (en) 2010-10-21
US20040106650A1 (en) 2004-06-03
RU2336267C2 (ru) 2008-10-20
ZA200501311B (en) 2006-10-25
CY1110745T1 (el) 2015-06-10
WO2004026826A1 (en) 2004-04-01
CN1681778A (zh) 2005-10-12
ZA200501557B (en) 2005-09-08
TWI286132B (en) 2007-09-01
KR100681586B1 (ko) 2007-02-09
DE60333202D1 (de) 2010-08-12
EP1542970B1 (de) 2010-06-30
MY135696A (en) 2008-06-30
NO20050665L (no) 2005-04-18
AR041298A1 (es) 2005-05-11
CN1681777A (zh) 2005-10-12
BRPI0314631B1 (pt) 2018-04-17
HRP20050261A2 (en) 2006-05-31
CA2498785C (en) 2011-07-26
PE20050078A1 (es) 2005-02-28
RU2336268C2 (ru) 2008-10-20
JP2006503833A (ja) 2006-02-02
US20040116707A1 (en) 2004-06-17
CN1681779A (zh) 2005-10-12
JP4335140B2 (ja) 2009-09-30
PL376018A1 (en) 2005-12-12
AR041297A1 (es) 2005-05-11
CN100383118C (zh) 2008-04-23
ES2338646T3 (es) 2010-05-11
HRP20050263B1 (hr) 2013-09-30
AU2003273901B2 (en) 2008-07-10
US7122562B2 (en) 2006-10-17
NZ538049A (en) 2007-05-31
AU2003267381A1 (en) 2004-04-08
KR20050057466A (ko) 2005-06-16
GT200300204A (es) 2004-04-29
TW200408624A (en) 2004-06-01
NZ538048A (en) 2007-05-31
AU2003270213A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE459601T1 (de) Pyrrolidonderivate als mao-b hemmer
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DE60226775D1 (de) Azaindolylalkylaminderivate als 5-hydroxytryptamin-6-liganden
DK1492934T3 (da) Dørenhed
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
NO20041958L (no) Stovtett plagg
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
BR0311793B1 (pt) Projétil de neblina
NO20023047D0 (no) Kompenseringsanordning
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DE602004017206D1 (de) Benzazepin-derivate als mao-b-hemmer
DE60336338D1 (de) Sulfonylaminopyrazole als pestizide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition